

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Aug-2023  
 Document Type: USP Monographs  
 DocId: GUID-01883BEE-8063-4955-AAC3-78B37FBA8EC6\_2\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M5591\\_02\\_01](https://doi.org/10.31003/USPNF_M5591_02_01)  
 DOI Ref: u4dd1

© 2025 USPC  
 Do not distribute

Add the following:

## ^Sildenafil Injection

### DEFINITION

Sildenafil Injection is a sterile solution of Sildenafil Citrate in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of sildenafil ( $C_{22}H_{30}N_6O_4S$ ). It also contains dextrose.

### IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Solution A:** 15.4 g/L of [ammonium acetate](#) in [water](#)

**Mobile phase:** [Acetonitrile](#) and *Solution A* (50:50)

**Standard solution:** 0.11 mg/mL of [USP Sildenafil Citrate RS](#) in *Mobile phase*. Sonicate to dissolve if necessary.

**Sample solution:** Nominally 0.08 mg/mL of sildenafil prepared as follows. Transfer 5 mL of Injection to a 50-mL volumetric flask and dilute with *Mobile phase* to volume.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 245 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

**Column:** 4.6-mm × 15-cm; 5-μm packing [L1](#)

**Flow rate:** 1 mL/min

**Injection volume:** 20 μL

**Run time:** NLT 1.6 times the retention time of sildenafil

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 1.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sildenafil ( $C_{22}H_{30}N_6O_4S$ ) in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response of sildenafil from the *Sample solution*

$r_S$  = peak response of sildenafil from the *Standard solution*

$C_S$  = concentration of [USP Sildenafil Citrate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of sildenafil in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of sildenafil, 474.58

$M_{r2}$  = molecular weight of sildenafil citrate, 666.70

**Acceptance criteria:** 95.0%–105.0%

## IMPURITIES

### • ORGANIC IMPURITIES

**Dilute phosphoric acid:** 10% (v/v) [phosphoric acid](#) in [water](#)

**Buffer:** 3.5 g/L of [potassium phosphate, dibasic](#) in [water](#). Adjust with *Dilute phosphoric acid* to a pH of 7.0.

**Solution A:** [Acetonitrile](#) and *Buffer* (14:86)

**Solution B:** [Acetonitrile](#) and *Buffer* (74:26)

**Mobile phase:** See [Table 1](#).

**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	78	22
5	78	22
20	50	50
30	40	60
35	78	22
40	78	22

**Diluent:** [Methanol](#) and [water](#) (50:50)

**Standard stock solution:** 0.46 mg/mL of [USP Sildenafil Citrate RS](#) in [methanol](#). Sonicate to dissolve if necessary.

**Standard solution:** 1.15 µg/mL of [USP Sildenafil Citrate RS](#) from the *Standard stock solution* in *Diluent*

**Sensitivity solution:** 0.575 µg/mL of [USP Sildenafil Citrate RS](#) from the *Standard solution* in *Diluent*

**Sample solution:** Nominally 0.4 mg/mL of sildenafil prepared as follows. Transfer 5 mL of Injection to a 10-mL volumetric flask and dilute with [methanol](#) to volume.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 240 nm

**Column:** 4.6-mm × 15-cm; 5-µm packing [L1](#)

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

### System suitability

**Samples:** *Standard solution* and *Sensitivity solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0, *Standard solution*

**Relative standard deviation:** NMT 5.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of sildenafil N-oxide and any unspecified degradation product in the portion of Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/F) \times 100$$

$r_U$  = peak response of each degradation product from the *Sample solution*

$r_S$  = peak response of sildenafil from the *Standard solution*

$C_S$  = concentration of [USP Sildenafil Citrate RS](#) in the *Standard solution* (mg/mL)

- $C_U$  = nominal concentration of sildenafil in the *Sample solution* (mg/mL)
- $M_{r1}$  = molecular weight of sildenafil, 474.58
- $M_{r2}$  = molecular weight of sildenafil citrate, 666.70
- $F$  = relative response factor (see [Table 2](#))

**Acceptance criteria:** See [Table 2](#). The reporting threshold is 0.1%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Sildenafil N-oxide <sup>a</sup>	0.44	0.95	0.2
Sildenafil	1.0	—	—
Any unspecified degradation product	—	1.00	0.2
Total degradation products	—	—	0.5

<sup>a</sup> 4-[(4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl]-1-methylpiperazine 1-oxide.

SPECIFIC TESTS

- [pH \(791\)](#): 3.5–4.5
- [PARTICULATE MATTER IN INJECTIONS \(788\)](#): Meets the requirements
- [STERILITY TESTS \(71\)](#): Meets the requirements
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): Meets the requirements

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE:** Preserve in single-dose glass containers. Store at controlled room temperature.
- [USP REFERENCE STANDARDS \(11\)](#).  
[USP 5-Hydroxymethylfurfural RS](#)  
5-(Hydroxymethyl)furan-2-carbaldehyde.  
 $C_6H_6O_3$  126.11  
[USP Sildenafil Citrate RS](#) ▲ (USP 1-Aug-2023)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
SILDENAFIL INJECTION	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. 47(6)

**Current DocID:** GUID-01883BEE-8063-4955-AAC3-78B37FBA8EC6\_2\_en-US  
**DOI:** [https://doi.org/10.31003/USPNF\\_M5591\\_02\\_01](https://doi.org/10.31003/USPNF_M5591_02_01)  
**DOI ref:** [u4dd1](#)